$ACHC
Acadia Healthcare Company, Inc.

2013 Q2 Form 10-Q Financial Statement

#000119312513312513 Filed on July 31, 2013

View on sec.gov

Income Statement

Concept 2013 Q2 2012 Q2
Revenue $177.5M $100.5M
YoY Change 76.56% 58.13%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $122.1M $70.30M
YoY Change 73.68% 5.08%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $4.200M $1.700M
YoY Change 147.06% -15.0%
% of Gross Profit
Operating Expenses $157.2M $90.51M
YoY Change 73.69% 21.16%
Operating Profit
YoY Change
Interest Expense $9.445M $7.471M
YoY Change 26.42% -473.55%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income $20.29M $10.02M
YoY Change 102.5% -152.89%
Income Tax $8.020M $3.919M
% Of Pretax Income 39.52% 39.11%
Net Earnings $12.20M $5.909M
YoY Change 106.41% -127.03%
Net Earnings / Revenue 6.87% 5.88%
Basic Earnings Per Share $0.24 $0.16
Diluted Earnings Per Share $0.24 $0.16
COMMON SHARES
Basic Shares Outstanding 50.01M shares 36.51M shares
Diluted Shares Outstanding 50.28M shares 36.70M shares

Balance Sheet

Concept 2013 Q2 2012 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $7.400M $120.2M
YoY Change -93.84%
Cash & Equivalents $7.399M $120.2M
Short-Term Investments
Other Short-Term Assets $19.99M $18.30M
YoY Change 9.22%
Inventory
Prepaid Expenses
Receivables $85.87M $45.70M
Other Receivables $0.00 $0.00
Total Short-Term Assets $127.1M $184.1M
YoY Change -30.97%
LONG-TERM ASSETS
Property, Plant & Equipment $312.1M $112.8M
YoY Change 176.73%
Goodwill $630.7M
YoY Change
Intangibles $18.84M
YoY Change
Long-Term Investments
YoY Change
Other Assets $25.35M $18.00M
YoY Change 40.83%
Total Long-Term Assets $987.1M $402.4M
YoY Change 145.3%
TOTAL ASSETS
Total Short-Term Assets $127.1M $184.1M
Total Long-Term Assets $987.1M $402.4M
Total Assets $1.114B $586.5M
YoY Change 89.97%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $28.07M $7.900M
YoY Change 255.34%
Accrued Expenses $17.17M $26.40M
YoY Change -34.96%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $13.31M $10.00M
YoY Change 33.05%
Total Short-Term Liabilities $86.68M $44.30M
YoY Change 95.66%
LONG-TERM LIABILITIES
Long-Term Debt $556.3M $288.6M
YoY Change 92.75%
Other Long-Term Liabilities $18.11M $7.200M
YoY Change 151.53%
Total Long-Term Liabilities $574.4M $295.8M
YoY Change 94.18%
TOTAL LIABILITIES
Total Short-Term Liabilities $86.68M $44.30M
Total Long-Term Liabilities $574.4M $295.8M
Total Liabilities $663.3M $340.1M
YoY Change 95.04%
SHAREHOLDERS EQUITY
Retained Earnings -$8.242M
YoY Change
Common Stock $500.0K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $450.8M $246.3M
YoY Change
Total Liabilities & Shareholders Equity $1.114B $586.5M
YoY Change 89.97%

Cashflow Statement

Concept 2013 Q2 2012 Q2
OPERATING ACTIVITIES
Net Income $12.20M $5.909M
YoY Change 106.41% -127.03%
Depreciation, Depletion And Amortization $4.200M $1.700M
YoY Change 147.06% -15.0%
Cash From Operating Activities $28.30M $5.600M
YoY Change 405.36% 86.67%
INVESTING ACTIVITIES
Capital Expenditures -$20.90M -$17.60M
YoY Change 18.75% 282.61%
Acquisitions
YoY Change
Other Investing Activities -$99.80M $1.200M
YoY Change -8416.67% -100.67%
Cash From Investing Activities -$120.7M -$16.40M
YoY Change 635.98% -91.04%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $139.0M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 130.1M
YoY Change -100.0% -25.91%
NET CHANGE
Cash From Operating Activities 28.30M 5.600M
Cash From Investing Activities -120.7M -16.40M
Cash From Financing Activities 0.000 130.1M
Net Change In Cash -92.40M 119.3M
YoY Change -177.45% -2751.11%
FREE CASH FLOW
Cash From Operating Activities $28.30M $5.600M
Capital Expenditures -$20.90M -$17.60M
Free Cash Flow $49.20M $23.20M
YoY Change 112.07% 205.26%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2011Q4 us-gaap Long Term Debt
LongTermDebt
150000000
CY2012Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9487500 shares
CY2012Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
15.50
CY2012Q2 us-gaap Common Stock Discount On Shares
CommonStockDiscountOnShares
7400000
CY2012Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
7000000 shares
CY2012Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
22.50
CY2012Q4 us-gaap Common Stock Discount On Shares
CommonStockDiscountOnShares
7300000
CY2012Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1050000 shares
CY2013Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
50513783 shares
CY2012Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
120176000
CY2013Q2 us-gaap Number Of States In Which Entity Operates
NumberOfStatesInWhichEntityOperates
21 State
CY2013Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
50037767 shares
CY2013Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
126746 shares
CY2013Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
50037767 shares
CY2013Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
20.70
CY2013Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
805609 shares
CY2013Q2 us-gaap Equity Method Investment Ownership Percentage
EquityMethodInvestmentOwnershipPercentage
1.00 pure
CY2013Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
4700000 shares
CY2013Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
8250 shares
CY2013Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2013Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
8.83
CY2013Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
90000000 shares
CY2013Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2013Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2013Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2013Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
14.00
CY2013Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2013Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
17171000
CY2013Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
556276000
CY2013Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
20717000
CY2013Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
458582000
CY2013Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
28072000
CY2013Q2 us-gaap Business Combination Assets And Liabilities Arising From Contingencies Amount Recognized Other Than At Fair Value
BusinessCombinationAssetsAndLiabilitiesArisingFromContingenciesAmountRecognizedOtherThanAtFairValue
6120000
CY2013Q2 us-gaap Liabilities Current
LiabilitiesCurrent
86679000
CY2013Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
28131000
CY2013Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
18110000
CY2013Q2 us-gaap Stockholders Equity
StockholdersEquity
450840000
CY2013Q2 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
11629000
CY2013Q2 us-gaap Line Of Credit Facility Remaining Borrowing Capacity
LineOfCreditFacilityRemainingBorrowingCapacity
99600000
CY2013Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-8242000
CY2013Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
1580000
CY2013Q2 us-gaap Common Stock Value
CommonStockValue
500000
CY2013Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1114172000
CY2013Q2 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
2267000
CY2013Q2 us-gaap Long Term Debt
LongTermDebt
569581000
CY2013Q2 us-gaap Liabilities
Liabilities
663332000
CY2013Q2 us-gaap Business Combination Assets And Liabilities Arising From Contingencies Amount Recognized
BusinessCombinationAssetsAndLiabilitiesArisingFromContingenciesAmountRecognized
6120000
CY2013Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
13305000
CY2013Q2 us-gaap Assets Current
AssetsCurrent
127089000
CY2011Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.74
CY2013Q2 us-gaap Goodwill
Goodwill
630749000
CY2013Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
18838000
CY2013Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
25349000
CY2013Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
800000
CY2013Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
0
CY2013Q2 us-gaap Assets
Assets
1114172000
CY2013Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7399000
CY2013Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
85872000
CY2013Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
600000
CY2013Q2 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
17071000
CY2013Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
332864000
CY2013Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
3300000
CY2013Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
3347000
CY2013Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
10040000
CY2013Q2 us-gaap Other Assets Current
OtherAssetsCurrent
19988000
CY2013Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
500000
CY2013Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
300000
CY2013Q2 us-gaap Deferred Tax Assets Net Current
DeferredTaxAssetsNetCurrent
13830000
CY2013Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
312147000
CY2013Q2 achc Intangible Assets Accumulated Amortization Carrying Amount
IntangibleAssetsAccumulatedAmortizationCarryingAmount
1580000
CY2013Q2 achc Indefinite Lived Intangible Assets Excluding Goodwill Accumulated Amortization
IndefiniteLivedIntangibleAssetsExcludingGoodwillAccumulatedAmortization
CY2013Q2 achc Intangible Assets Gross Carrying Amount
IntangibleAssetsGrossCarryingAmount
20418000
CY2013Q2 achc Number Of Beds
NumberOfBeds
3700 Beds
CY2011Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
346821 shares
CY2012Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
90000000 shares
CY2012Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2012Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2012Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2012Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
16341000
CY2012Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
465638000
CY2012Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
13030000
CY2012Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
456228000
CY2012Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
19081000
CY2012Q4 us-gaap Business Combination Assets And Liabilities Arising From Contingencies Amount Recognized Other Than At Fair Value
BusinessCombinationAssetsAndLiabilitiesArisingFromContingenciesAmountRecognizedOtherThanAtFairValue
6120000
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
61118000
CY2011Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
947000
CY2012Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
49887300 shares
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
164062 shares
CY2012Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
49887300 shares
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
13.13
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
555097 shares
CY2012Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
6.63
CY2012Q4 us-gaap Liabilities Current
LiabilitiesCurrent
71851000
CY2012Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
28749000
CY2012Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
12376000
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
432550000
CY2012Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
7484000
CY2012Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-24177000
CY2012Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
1174000
CY2012Q4 us-gaap Common Stock Value
CommonStockValue
499000
CY2012Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
983413000
CY2012Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
998000
CY2012Q4 us-gaap Long Term Debt
LongTermDebt
473318000
CY2012Q4 us-gaap Liabilities
Liabilities
550863000
CY2012Q4 us-gaap Business Combination Assets And Liabilities Arising From Contingencies Amount Recognized
BusinessCombinationAssetsAndLiabilitiesArisingFromContingenciesAmountRecognized
6120000
CY2012Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
7680000
CY2012Q4 us-gaap Assets Current
AssetsCurrent
140981000
CY2012Q4 us-gaap Goodwill
Goodwill
557402000
CY2012Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
15988000
CY2012Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
32100000
CY2012Q4 us-gaap Assets
Assets
983413000
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
49399000
CY2012Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
63870000
CY2012Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
13815000
CY2012Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
249972000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
49961000 shares
dei Entity Central Index Key
EntityCentralIndexKey
0001520697
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
CY2012Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
2707000
CY2012Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
3347000
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
5632000
CY2012Q4 us-gaap Other Assets Current
OtherAssetsCurrent
16332000
CY2012Q4 us-gaap Deferred Tax Assets Net Current
DeferredTaxAssetsNetCurrent
11380000
CY2012Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
236942000
CY2012Q4 achc Intangible Assets Accumulated Amortization Carrying Amount
IntangibleAssetsAccumulatedAmortizationCarryingAmount
1174000
CY2012Q4 achc Indefinite Lived Intangible Assets Excluding Goodwill Accumulated Amortization
IndefiniteLivedIntangibleAssetsExcludingGoodwillAccumulatedAmortization
CY2012Q4 achc Intangible Assets Gross Carrying Amount
IntangibleAssetsGrossCarryingAmount
17162000
dei Entity Registrant Name
EntityRegistrantName
Acadia Healthcare Company, Inc.
dei Amendment Flag
AmendmentFlag
false
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2013
dei Document Type
DocumentType
10-Q
dei Document Period End Date
DocumentPeriodEndDate
2013-06-30
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
10.13
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
372400 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.009 pure
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.32
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
50196000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.40 pure
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
235000 shares
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.32
us-gaap Nature Of Operations
NatureOfOperations
<div> <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td valign="top" width="4%" align="left"><font style="FONT-FAMILY: Times New Roman" size="2"><b>1.</b></font></td> <td valign="top" align="left"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Description of Business and Basis of Presentation</b></font></td> </tr> </table> <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Description of Business</i></b></font></p> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">Acadia Healthcare Company, Inc. (the &#x201C;Company&#x201D;) develops and operates inpatient psychiatric facilities, residential treatment centers, group homes, substance abuse facilities and facilities providing outpatient behavioral healthcare services to serve the behavioral health and recovery needs of communities throughout the United States. At June&#xA0;30, 2013, the Company operated 46 behavioral healthcare facilities with over 3,700 licensed beds in 21 states and Puerto Rico.</font></p> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Basis of Presentation</i></b></font></p> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">The business of the Company is conducted through limited liability companies and C-corporations, each of which is a direct or indirect wholly-owned subsidiary of the Company. The Company&#x2019;s consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, all of which are 100% owned. All significant intercompany accounts and transactions have been eliminated in consolidation.</font></p> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#x201C;GAAP&#x201D;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for fair presentation of our financial position and results of operations have been included. The Company&#x2019;s fiscal year ends on December&#xA0;31 and interim results are not necessarily indicative of results for a full year or any other interim period. The condensed consolidated balance sheet at December&#xA0;31, 2012 has been derived from the audited financial statements as of that date. The information contained in these condensed consolidated financial statements should be read in conjunction with the Company&#x2019;s consolidated financial statements and notes thereto for the fiscal year ended December&#xA0;31, 2012 included in the Company&#x2019;s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March&#xA0;1, 2013. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates.</font></p> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">Certain reclassifications have been made to prior years to conform to the current year presentation.</font></p> </div>
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y5M5D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y6M
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
29.34
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
28308000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
11.13
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
27950000
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
0.33
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
13350 shares
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
-0.01
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P4Y2M1D
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
108538 shares
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
-0.01
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
0.33
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
20.39
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
700000 shares
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
27023000
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
554000
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
-390000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-14000
us-gaap Payments To Acquire Real Estate
PaymentsToAcquireRealEstate
3959000
us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
350859000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
10557000
us-gaap Goodwill Other Changes
GoodwillOtherChanges
977000
us-gaap Net Income Loss
NetIncomeLoss
15935000
us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
16325000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
29709000
us-gaap Health Care Organization Revenue Net Of Patient Service Revenue Provisions
HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
338707000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1038000
us-gaap Health Care Organization Medical Supplies And Drugs Expense
HealthCareOrganizationMedicalSuppliesAndDrugsExpense
18211000
us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
74324000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-4369000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
86003000
us-gaap Deferred Tax Expense From Stock Options Exercised
DeferredTaxExpenseFromStockOptionsExercised
1200000
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
121731000
us-gaap Health Care Organization Revenue
HealthCareOrganizationRevenue
348656000
us-gaap Repayments Of Debt
RepaymentsOfDebt
52500000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2100000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
4307000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
807000
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-107000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-9350000
us-gaap Liabilities Assumed1
LiabilitiesAssumed1
12647000
us-gaap Repayments Of Secured Debt
RepaymentsOfSecuredDebt
1875000
us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
37079000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
5392000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
1886000
us-gaap Share Based Compensation
ShareBasedCompensation
2413000
us-gaap Proceeds And Excess Tax Benefit From Sharebased Compensation
ProceedsAndExcessTaxBenefitFromSharebasedCompensation
1211000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
7834000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-42000000
us-gaap Interest Expense
InterestExpense
18207000
us-gaap Severance Costs1
SeveranceCosts1
1026000
us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
2829000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-155953000
us-gaap Fair Value Of Assets Acquired
FairValueOfAssetsAcquired
146062000
us-gaap Health Care Organization Patient Service Revenue Provisionfor Bad Debts
HealthCareOrganizationPatientServiceRevenueProvisionforBadDebts
9949000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
233000
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
50000000
us-gaap Unrecognized Tax Benefits Income Tax Penalties Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense
15700000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
7834000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
1110000
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
150000000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
400000
us-gaap Cash Provided By Used In Operating Activities Discontinued Operations
CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
-358000
us-gaap Professional Fees
ProfessionalFees
18338000
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
4721000
us-gaap Labor And Related Expense
LaborAndRelatedExpense
195115000
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
458000
us-gaap Operating Expenses
OperatingExpenses
311684000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
10698000
achc Weighted Average Vesting Period
WeightedAverageVestingPeriod
P1Y7M21D
achc Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled In Period Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodAggregateIntrinsicValue
achc Share Based Compensation Arrangement By Share Based Payment Award Rollover Options Issued In Period Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardRolloverOptionsIssuedInPeriodWeightedAverageRemainingContractualTerm
P9Y7M2D
achc Share Based Compensation Arrangement By Share Based Payment Stock Options Granted Term
ShareBasedCompensationArrangementByShareBasedPaymentStockOptionsGrantedTerm
P10Y
achc Business Acquisitions Pro Forma Income Loss From Continuing Operations Before Income Taxes
BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeIncomeTaxes
28614000
achc Payment Of Debt Redemption Premium
PaymentOfDebtRedemptionPremium
-6759000
achc Share Based Compensation Arrangement By Share Based Payment Award
ShareBasedCompensationArrangementByShareBasedPaymentAward
0.25 pure
achc Capitalized Cost Incurred
CapitalizedCostIncurred
300000
achc Legal Accounting And Other Fees
LegalAccountingAndOtherFees
1803000
achc Number Of Facilities
NumberOfFacilities
46 Facility
achc Share Based Compensation Arrangement By Share Based Payment Award Rollover Options Issued In Period Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardRolloverOptionsIssuedInPeriodIntrinsicValue
1357000
achc Deposits Related To Acquisition
DepositsRelatedToAcquisition
11684000
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.28
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
34514000 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
201000 shares
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.28
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
10742000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
10546000
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
0.27
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
34313000 shares
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
0.01
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0.01
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
0.27
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
600000 shares
us-gaap Disposal Group Including Discontinued Operation Revenue
DisposalGroupIncludingDiscontinuedOperationRevenue
3570000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
15012000
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
-1400000
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
160000
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
90466000
us-gaap Health Care Organization Revenue
HealthCareOrganizationRevenue
194020000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
1138000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-313000
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
2214000
us-gaap Liabilities Assumed1
LiabilitiesAssumed1
2833000
us-gaap Repayments Of Secured Debt
RepaymentsOfSecuredDebt
4000000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-21000
us-gaap Payments To Acquire Real Estate
PaymentsToAcquireRealEstate
13886000
us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
311322000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
6692000
us-gaap Net Income Loss
NetIncomeLoss
9588000
us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
9428000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
7619000
us-gaap Health Care Organization Revenue Net Of Patient Service Revenue Provisions
HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
190093000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-2805000
us-gaap Health Care Organization Medical Supplies And Drugs Expense
HealthCareOrganizationMedicalSuppliesAndDrugsExpense
9317000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
327000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
159083000
us-gaap Deferred Tax Expense From Stock Options Exercised
DeferredTaxExpenseFromStockOptionsExercised
0
us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
19388000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
4854000
us-gaap Share Based Compensation
ShareBasedCompensation
1170000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
3256000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
59058000
us-gaap Interest Expense
InterestExpense
14753000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
139034000
us-gaap Severance Costs1
SeveranceCosts1
36000
us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
1365000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-110571000
us-gaap Fair Value Of Assets Acquired
FairValueOfAssetsAcquired
93299000
us-gaap Health Care Organization Patient Service Revenue Provisionfor Bad Debts
HealthCareOrganizationPatientServiceRevenueProvisionforBadDebts
3927000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
187000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3256000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
1224000
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
25000000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
300000
us-gaap Cash Provided By Used In Operating Activities Discontinued Operations
CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
-196000
us-gaap Professional Fees
ProfessionalFees
8831000
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
4469000
us-gaap Labor And Related Expense
LaborAndRelatedExpense
113702000
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
1860000
us-gaap Operating Expenses
OperatingExpenses
175081000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
5584000
achc Business Acquisitions Pro Forma Income Loss From Continuing Operations Before Income Taxes
BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeIncomeTaxes
29225000
achc Capitalized Cost Incurred
CapitalizedCostIncurred
300000
achc Legal Accounting And Other Fees
LegalAccountingAndOtherFees
1329000
CY2012Q2 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
700000
CY2012Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
139000000
CY2012Q4 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1000000
CY2012Q4 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
172800000
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.012 pure
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.42 pure
CY2012 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y6M11D
CY2012 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y3M18D
CY2012 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
16.36
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
6.93
CY2012 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
8.01
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
429498 shares
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
97028 shares
CY2012 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P3Y7M2D
CY2012 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
124194 shares
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
14.70
CY2012 achc Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled In Period Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodAggregateIntrinsicValue
CY2012 achc Share Based Compensation Arrangement By Share Based Payment Award Rollover Options Issued In Period Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardRolloverOptionsIssuedInPeriodWeightedAverageRemainingContractualTerm
P9Y2M19D
CY2012 achc Share Based Compensation Arrangement By Share Based Payment Award Rollover Options Issued In Period Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardRolloverOptionsIssuedInPeriodIntrinsicValue
2960000
CY2012 achc Share Based Compensation Arrangement By Share Based Payment Award Options Granted Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm
P4Y6M
CY2012Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.16
CY2012Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
36695000 shares
CY2012Q2 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
188000 shares
CY2012Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.16
CY2012Q2 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
0.17
CY2012Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
36507000 shares
CY2012Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
-0.01
CY2012Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
-0.01
CY2012Q2 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
0.17
CY2012Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
600000 shares
CY2012Q2 us-gaap Disposal Group Including Discontinued Operation Revenue
DisposalGroupIncludingDiscontinuedOperationRevenue
1795000
CY2012Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
10020000
CY2012Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
-192000
CY2012Q2 us-gaap Health Care Organization Revenue
HealthCareOrganizationRevenue
102752000
CY2012Q2 us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
159027000
CY2012Q2 us-gaap Net Income Loss
NetIncomeLoss
5909000
CY2012Q2 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
6101000
CY2012Q2 us-gaap Health Care Organization Revenue Net Of Patient Service Revenue Provisions
HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
100530000
CY2012Q2 us-gaap Health Care Organization Medical Supplies And Drugs Expense
HealthCareOrganizationMedicalSuppliesAndDrugsExpense
4872000
CY2012Q2 us-gaap Deferred Tax Expense From Stock Options Exercised
DeferredTaxExpenseFromStockOptionsExercised
0
CY2012Q2 us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
10407000
CY2012Q2 us-gaap Share Based Compensation
ShareBasedCompensation
592000
CY2012Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1646000
CY2012Q2 us-gaap Interest Expense
InterestExpense
7471000
CY2012Q2 us-gaap Severance Costs1
SeveranceCosts1
29000
CY2012Q2 us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
670000
CY2012Q2 us-gaap Health Care Organization Patient Service Revenue Provisionfor Bad Debts
HealthCareOrganizationPatientServiceRevenueProvisionforBadDebts
2222000
CY2012Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
100000
CY2012Q2 us-gaap Professional Fees
ProfessionalFees
4658000
CY2012Q2 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
2227000
CY2012Q2 us-gaap Labor And Related Expense
LaborAndRelatedExpense
58559000
CY2012Q2 us-gaap Operating Expenses
OperatingExpenses
90510000
CY2012Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3919000
CY2012Q2 achc Business Acquisitions Pro Forma Income Loss From Continuing Operations Before Income Taxes
BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeIncomeTaxes
17879000
CY2013Q2 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
0.24
CY2013Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
400000 shares
CY2013Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
20291000
CY2013Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
-74000
CY2013Q2 us-gaap Health Care Organization Revenue
HealthCareOrganizationRevenue
182951000
CY2013Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1700000
CY2013Q2 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
CY2013Q2 us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
179558000
CY2013Q2 us-gaap Net Income Loss
NetIncomeLoss
12197000
CY2012Q2 achc Legal Accounting And Other Fees
LegalAccountingAndOtherFees
641000
CY2013Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.24
CY2013Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
50282000 shares
CY2013Q2 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
273000 shares
CY2013Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.24
CY2013Q2 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
0.24
CY2013Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
50009000 shares
CY2013Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
CY2013Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
CY2013Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Accelerated Vesting Number
SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber
20090 shares
CY2013Q2 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
12271000
CY2013Q2 us-gaap Health Care Organization Revenue Net Of Patient Service Revenue Provisions
HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
177494000
CY2013Q2 us-gaap Health Care Organization Medical Supplies And Drugs Expense
HealthCareOrganizationMedicalSuppliesAndDrugsExpense
9613000
CY2013Q2 us-gaap Deferred Tax Expense From Stock Options Exercised
DeferredTaxExpenseFromStockOptionsExercised
600000
CY2013Q2 us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
20096000
CY2013Q2 us-gaap Share Based Compensation
ShareBasedCompensation
1812000
CY2013Q2 us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
1355000
CY2013Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
4212000
CY2013Q2 us-gaap Interest Expense
InterestExpense
9445000
CY2013Q2 us-gaap Severance Costs1
SeveranceCosts1
557000
CY2013Q2 us-gaap Health Care Organization Patient Service Revenue Provisionfor Bad Debts
HealthCareOrganizationPatientServiceRevenueProvisionforBadDebts
5457000
CY2013Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Accelerated Compensation Cost
ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost
600000
CY2013Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
200000
CY2013Q2 us-gaap Professional Fees
ProfessionalFees
9324000
CY2013Q2 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
2394000
CY2013Q2 us-gaap Labor And Related Expense
LaborAndRelatedExpense
100764000
CY2013Q2 us-gaap Operating Expenses
OperatingExpenses
157203000
CY2013Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
8020000
CY2013Q2 achc Business Acquisitions Pro Forma Income Loss From Continuing Operations Before Income Taxes
BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeIncomeTaxes
20848000
CY2013Q2 achc Legal Accounting And Other Fees
LegalAccountingAndOtherFees
798000

Files In Submission

Name View Source Status
0001193125-13-312513-index-headers.html Edgar Link pending
0001193125-13-312513-index.html Edgar Link pending
0001193125-13-312513.txt Edgar Link pending
0001193125-13-312513-xbrl.zip Edgar Link pending
achc-20130630.xml Edgar Link completed
achc-20130630.xsd Edgar Link pending
achc-20130630_cal.xml Edgar Link unprocessable
achc-20130630_def.xml Edgar Link unprocessable
achc-20130630_lab.xml Edgar Link unprocessable
achc-20130630_pre.xml Edgar Link unprocessable
d560710d10q.htm Edgar Link pending
d560710dex101.htm Edgar Link pending
d560710dex311.htm Edgar Link pending
d560710dex312.htm Edgar Link pending
d560710dex32.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
R1.htm Edgar Link pending
R1.xml Edgar Link unprocessable
R10.htm Edgar Link pending
R10.xml Edgar Link unprocessable
R11.htm Edgar Link pending
R11.xml Edgar Link unprocessable
R12.htm Edgar Link pending
R12.xml Edgar Link unprocessable
R13.htm Edgar Link pending
R13.xml Edgar Link unprocessable
R14.htm Edgar Link pending
R14.xml Edgar Link unprocessable
R15.htm Edgar Link pending
R15.xml Edgar Link unprocessable
R16.htm Edgar Link pending
R16.xml Edgar Link unprocessable
R17.htm Edgar Link pending
R17.xml Edgar Link unprocessable
R18.htm Edgar Link pending
R18.xml Edgar Link unprocessable
R19.htm Edgar Link pending
R19.xml Edgar Link unprocessable
R2.htm Edgar Link pending
R2.xml Edgar Link unprocessable
R20.htm Edgar Link pending
R20.xml Edgar Link unprocessable
R21.htm Edgar Link pending
R21.xml Edgar Link unprocessable
R22.htm Edgar Link pending
R22.xml Edgar Link unprocessable
R23.htm Edgar Link pending
R23.xml Edgar Link unprocessable
R24.htm Edgar Link pending
R24.xml Edgar Link unprocessable
R25.htm Edgar Link pending
R25.xml Edgar Link unprocessable
R26.htm Edgar Link pending
R26.xml Edgar Link unprocessable
R27.htm Edgar Link pending
R27.xml Edgar Link unprocessable
R28.htm Edgar Link pending
R28.xml Edgar Link unprocessable
R29.htm Edgar Link pending
R29.xml Edgar Link unprocessable
R3.htm Edgar Link pending
R3.xml Edgar Link unprocessable
R30.htm Edgar Link pending
R30.xml Edgar Link unprocessable
R31.htm Edgar Link pending
R31.xml Edgar Link unprocessable
R32.htm Edgar Link pending
R32.xml Edgar Link unprocessable
R33.htm Edgar Link pending
R33.xml Edgar Link unprocessable
R34.htm Edgar Link pending
R34.xml Edgar Link unprocessable
R35.htm Edgar Link pending
R35.xml Edgar Link unprocessable
R36.htm Edgar Link pending
R36.xml Edgar Link unprocessable
R37.htm Edgar Link pending
R37.xml Edgar Link unprocessable
R38.htm Edgar Link pending
R38.xml Edgar Link unprocessable
R39.htm Edgar Link pending
R39.xml Edgar Link unprocessable
R4.htm Edgar Link pending
R4.xml Edgar Link unprocessable
R40.htm Edgar Link pending
R40.xml Edgar Link unprocessable
R41.htm Edgar Link pending
R41.xml Edgar Link unprocessable
R42.htm Edgar Link pending
R42.xml Edgar Link unprocessable
R43.htm Edgar Link pending
R43.xml Edgar Link unprocessable
R44.htm Edgar Link pending
R44.xml Edgar Link unprocessable
R45.htm Edgar Link pending
R45.xml Edgar Link unprocessable
R46.htm Edgar Link pending
R46.xml Edgar Link unprocessable
R47.htm Edgar Link pending
R47.xml Edgar Link unprocessable
R48.htm Edgar Link pending
R48.xml Edgar Link unprocessable
R49.htm Edgar Link pending
R49.xml Edgar Link unprocessable
R5.htm Edgar Link pending
R5.xml Edgar Link unprocessable
R50.htm Edgar Link pending
R50.xml Edgar Link unprocessable
R51.htm Edgar Link pending
R51.xml Edgar Link unprocessable
R52.htm Edgar Link pending
R52.xml Edgar Link unprocessable
R53.htm Edgar Link pending
R53.xml Edgar Link unprocessable
R54.htm Edgar Link pending
R54.xml Edgar Link unprocessable
R55.htm Edgar Link pending
R55.xml Edgar Link unprocessable
R6.htm Edgar Link pending
R6.xml Edgar Link unprocessable
R7.htm Edgar Link pending
R7.xml Edgar Link unprocessable
R8.htm Edgar Link pending
R8.xml Edgar Link unprocessable
R9.htm Edgar Link pending
R9.xml Edgar Link unprocessable
report.css Edgar Link pending
Show.js Edgar Link pending